

Januvia (sitagliptin) Prior Authorization Request Form Caterpillar Prescription Drug Benefit



Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:	·	
CITY:	STATE: ZIP CODE:	
PATIENT INSURANCE ID NUMBER:	•	
MALE FEMALE HEIGHT (IN/CM): WEIG	HT (LB/KG): ALLERGIES:	

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>https://magellanrx.com/member/external/commercial/common/doc/en-us/phi_disclosure_authorization.pdf</u>

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): ______AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: ______

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:	-	
CITY:	STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.









MEMBER'S LAST NAME:	R'S LAST NAME: MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
 Type 1 diabetes 		
□ Type 2 diabetes		
Other DiagnosisICD-10 C	Code(s):	
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A
Is the patient 18 years of age or older	? 🛛 Yes 🗆 No)
Is the patient already taking the requ		D
Is the patient's HbA1c 7% or greater? HbA1c must be taken within the past Copy of HbA1c level rquired.	6 months.	
Was the patient's most recent HbA1c	level, PRIOR to STARTING the requeste	d medication, 7.0% or greater?*
🗆 Yes 🗆 No		
*Copy of HbA1c level rquired.		
Is the patient currently on metformin	?* □ Yes □ No	
Does the patient had an inadequate r *Please provide documentation	esponse or intolerance to metform?	
Estimated glomerular filtration rate	the following contraindication to metfo (GFR) less than or equal to 45 mL/min/ s, portal hypertension, ascites, and/or l	/1.73 m2
Is the patient currently taking one of	the below? (Please Circle)	
Adlyxin (lixisenatide)		
 Glyxambi(linagliptin/empaglifloz 	in)	
 Byetta, Bydureon (exenatide) 		
 Janumet/Janumet XR (sitagliptin 	and metformin)	
 Tradjenta (linagliptin) 		
 Onglyza (saxagliptin) 		
Oseni (alogliptin-pioglitazone)		
Trulicity (dulaglutide)		
Victoza (liraglutide)		
Ozempic(semaglutide)		
Nesina (alogliptin)		
© 2017–2023 by Magellan Rx Management, LLC	. All Rights Reserved.	
Revision Date: 10/01/2022		Magellan Magellan



MANAGEMENT_{SM}





Phone: 877-228-7909 Fax: 800-424-7640

- Jentadueto (linagliptin and metformin)
- Kombiglyze XR (saxagliptin and metformin)
- Kazano (alogliptin and metformin)

Will the drug be discontinued?

Yes

No

- Adlyxin (lixisenatide)
- Glyxambi(linagliptin/empagliflozin)
- Byetta, Bydureon (exenatide)
- Janumet/Janumet XR (sitagliptin and metformin)
- Tradjenta (linagliptin)
- Onglyza (saxagliptin)
- Oseni (alogliptin-pioglitazone)
- Trulicity (dulaglutide)
- Victoza (liraglutide)
- Ozempic(semaglutide)
- Nesina (alogliptin)
- Jentadueto (linagliptin and metformin)
- Kombiglyze XR (saxagliptin and metformin)
- Kazano (alogliptin and metformin)

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

_ Date: _

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640 MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811



